Pomaglumetad
Top View
- Translating Advances in the Molecular Basis of Schizophrenia Into Novel Cognitive Treatment Strategies
- 2012 Annual Report Notice of 2013 Annual Meeting Proxy Statement Putting the Pieces Together the Lilly Promise Advancing Health
- Clinical Trials in Psychiatry: Focusing on Antipsychotic Development
- Mglur2/3 Agonist LY379268 Rescues NMDA and GABAA Receptor Level Deficits Induced in a Two-Hit Mouse Model of Schizophrenia
- Specific Activation of Mglu2 Induced IGF-1R Transactivation in Vitro
- PDF File of an Unedited Manuscript That Has Been Accepted for Publication
- ET Fast Forward
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- King's Research Portal
- Curriculum Vitae: Robert W. Baker
- A Roadmap for Development of Novel Antipsychotic Agents Based on a Risperidone Scaffold
- A Double-Blind, Placebo-Controlled Comparator Study of LY2140023
- Pomaglumetad Methionil (Also Known As POMA, LY-2140023)
- Mary-Anne Bellwood Mackay
- Mglur3 Knockout Mice Show a Working Memory Defect and an Enhanced Response to MK-801 in the T- and Y-Maze Cognitive Tests
- Update on New and Emerging Treatments for Schizophrenia
- Metabotropic Glutamate Receptor 2 Activation: Computational Predictions and Experimental Validation
- Proof of Mechanism and Target Engagement Of